


Q2/H1 2015 RESULTS

TJERK DE RUITER, EDDY VAN RHEDE 12/8/2015 VAN DER KLOOT


Highlights Q2 2015

- Organic net sales growth of 4.5%, mostly volume driven (4.1%)
 - Net sales growth of 23.4%; currencies add 17.4%
- EBITDA Q2 excluding one-off items increased organically by 23.1%
 - EBITDA € 40.1M (Q2 14: € 26.8M) supported by volume growth, positive currencies
- Acquisition of ADM lactic acid business (April 2015)
- Achieved 1/3rd (25 kT) PLA volume commitments through >15 letters of intent (May 2015)
- Streamline program: € 4.3M savings in Q2, YTD € 6.8M



Joint venture with MedinCell in Medical Biomaterials

- JV announced 10 August to supply resorbable polymers for controlled drug release
- Partner MedinCell developed very promising technology
 - Technology can provide a controlled release of drug for days, weeks or months
- Corbion will be responsible for manufacturing the (co-)polymers (PEG & PLA)





R&D roadmap – Progress in H1 2015


	YTD	YTD
€ million	2015	2014
R&D expenses cash-out	15.0	15.5
Capitalization	(1.8)	(2.0)
Amortization / depreciation	0.8	1.1
R&D expenses	14.1	14.6



	8.	6 - 6	development	and Develop	,0 ^{,1}
	Scoping	conce	Desile	rest	
Biobased Ingredients					
Ferments					
Animal Health					
Partially hydrogenated oil replacement					
Natural preservation					
Fiberlive (Biomaterials)					
CASE					
Enhanced freshness for industrial bread					

Biobased innvations

Lactide/PLA Gypsum free process Succinic acid (BASF JV) 2nd Generation Biomass FDCA



Testand Validate

Launch

Commercialscale

Current Description



Launch of a reformulated non PHO emulsifier portfolio Label friendly products for meat Signed co-development and licensing agreement CASE: Coatings; Adhesives; Sealants and Elastomer program Longer shelf life over competitive blends in bread

Letters of intent for 1/3rd of a future 75kT PLA plant Technology operational in NL factory Biobases succinic acid to replace fossil based succinic Gypsum- free lactic acid outside the food chain Demonstrated capability producing polymer-grade FDCA

Progress in our Biobased Ingredients R&D portfolio



Q2/H1 2015 Financials



Profit & Loss: Q2 and H1 2015

€ million	Q2	Q2*		YTD	YTD*	
	2015	2014		2015	2014	%
Net Sales	232.3	188.3	23.4%	452.3	371.0	21.9%
EBITDA excl. one-off items	40.1	26.8	49.6%	77.3	51.9	48.9%
EBITDA margin	17.3%	14.2%		17.1%	14.0%	
Depreciation & Amortization				(22.7)	(21.4)	
One-off items				(1.3)	(20.3)	
EBIT				53.3	10.2	
Financial income/expenses				(2.9)	(2.6)	
Result joint ventures/assoc.				(0.2)	(0.3)	
Taxes				(15.6)	(6.1)	
Result after tax				34.6	1.2	
EPS				0.55	0.00	

* Restatement 2014: EUR 0.2M in EBITDA excl. one-off items and EUR 0.9M in one-off items

- EBITDA excl. one-off items growth 50% in Q2 supported by:
 - Volume growth
 - Stronger USD
- EBITDA organic growth of 23% in Q2 2015
- H1 2015 Net result of € 34.6M
 - one-off items of € 1.3M
- EPS H1 2015: € 0.55




Sales Growth per segment in Q2 2015

	Total Growth	Currency	Total growth at constant currency	Acquisitions	Organic	Price/Mix	Volume
Biobased Ingredients	22.3%	17.3%	5.0%	1.5%	3.5%	-0.2%	3.7%
- Food	23.7%	18.6%	5.1%	1.7%	3.4%	-0.5%	3.9%
- Biochemicals	17.8%	13.0%	4.8%	0.8%	4.0%	1.4%	2.6%
Biobased Innovations	183.3%	34.0%	149.3%	0.0%	149.3%	98.6%	50.7%
Total	23.4%	17.4%	6.0%	1.5%	4.5%	0.4%	4.1%

- Net Sales Growth of 23.4%, driven by:
 - Organic: 4.5%
 - Currencies: 17.4%



EBITDA bridge Q2 2015



- Organic volume growth: 4.1%
- Strong performance in Meat causes negative mix effect
- Currency impact as \$ strengthened against Euro



Streamline program progress


Quarterly savings (€ million)	Q1 2015	Q2 2015	YTD 2015
Program Streamline	2.5	4.3	6.8

- Majority of Streamline program has been implemented:
 - Savings coming in faster than expected
 - Large remaining initiative: Closure of our Kansas Avenue powder blending plant
- Cost savings in Q2 of € 4.3M (Q1: € 2.5M)
- Total expected annual savings of € 20M (run-rate achieved in 2016) maintained



Biobased Ingredients

€ million	Q2 2015	Q2 2014	YTD 2015	YTD 2014
Net Sales	228.9	187.1	445.2	367.5
Organic growth	3.5%	1.0%	3.9%	1.7%
EBITDA excl. one-off items	40.8	30.1	80.1	57.9
Margin	17.8%	16.1%	18.0%	15.8%
ROCE	26.1%	19.9%	26.2%	19.8%




- Organic sales growth in Q2: 3.5%
- EBITDA margin increase to 17.8% (Q2 14: 16.1%)
- ROCE increased to 26.1% (HY14: 19.9%)



Business Segment Food

€ million	Q2 2015	Q2 2014	YTD 2014	YTD 2013
Net Sales	177.9	143.8	338.7	276.8
Organic growth	3.4%	-2.2%	3.4%	-1.8%
EBITDA excl. one-off items	34.5	27.1	65.1	50.1
Margin	19.4%	18.8%	19.2%	18.1%




- Organic growth in Q4: 3.4%
- Bakery: Q2 sales up due to consumer recovery and new products
- Meat:
 - Meat US grew: more clean label and less customer switch to LCiU
 - Meat RoW continued with good growth
- Other segments: Volume declines due to competitive environment




Business Segment Biochemicals

€ million	Q2 2015	Q2 2014	YTD 2015	YTD 2014
Net Sales	51.0	43.3	106.5	90.7
Organic growth	4.0%	13.0%	5.4%	13.6%
EBITDA excl. one-off items	10.8	9.8	23.4	19.3
Margin	21.2%	22.6%	22.0%	21.3%



- Electronics and Pharma market segment continued to perform well
- Agrochemical, Medical Biomaterials weaker in Q2 after stronger Q1
- Feed acidifiers impacted growth negatively in H1
- Comparatively weaker growth rates, also in H2, due to strong 2014




Biobased Innovations

€ million	Q2 2015	Q2 2014	YTD 2015	YTD 2014
Net Sales	3.4	1.3	7.1	3.5
Organic growth	149.3%	27.4%	85.5%	71.5%
EBITDA excl. one-off items	(0.8)	(3.2)	(2.8)	(6.0)
Margin	-23.8%	-257.2%	-39.8%	-170.6%


- EBITDA loss reduced:
 - Ramp-up in Bioplastics/PLA related Sales (mostly highheat)
- More R&D/pilot activity expected in H2
- Continued disciplined approach in developing new business platforms








Net debt/cash bridge H1 2015



- Net debt position of € 72.1M per end of June 2015
- Working Capital impacted our net debt position € 18.8M negatively mainly due to increased inventory and debtors
- Dividend & Extraordinary return to shareholders
 - € 83.1M cash-out in total



Capital Expenditures



Major capex projects in H1 2015

- Grandview facility
- ADM lactic acid business


Sale former HQ office

Significant upswing expected in H2 capex spending

- FY15 total expected in € 60-70M range
- Kansas/Totowa integration
- Grandview facility



Cash Flow



• Improving trend in free cash flow since H1 2013



Full Year Outlook 2015

Biobased Ingredients

- **Food**: Growth at the upper half of our guidance range (1-3%)
- **Biochemicals**: Growth near lower end guidance range (5-8%)
 - Reduction feed acidifiers
 - Challenging comparison to H2 2014
- Streamline savings: Majority of savings expected in 2015 rather than in 2016

Biobased Innovations

• R&D costs increase in H2

Total

• Slightly lower EBITDA excluding one-off items in H2, compared to H1 2015



Our strategy – Disciplined Value Creation

